Palbocilif 125 mg
Rx — Prescription only
Oncology Capsule
Targeted therapy for HR+/HER2− breast cancer. A CDK4/6 inhibitor, presented as hard gelatin capsules for oral use.
Composition
Palbociclib 125 mg
Strength
125 mg
Pack size
1 x 28 Capsules
Therapeutic category
Oncology
Indications
Breast Cancer (HR+/HER2−)
Dosage and directions
For oral use. To be prescribed, dosed and administered under the supervision of a qualified oncologist. Refer to the approved pack insert for the full prescribing information.
Marketed by
LifeSpark Pharma Private Limited
Manufactured at WHO-GMP approved partner facilities. The
manufacturing plant and licence number are printed on the pack.
Keep out of reach of children.
Products to be used as directed. Read the label carefully. Consult your physician.
To be sold by retail on the prescription of a registered medical practitioner only.
This page is a summary. The pack insert supplied with the product is the authoritative document; where the two differ, the insert prevails. Experienced a side effect? Report it here.
Enquire about Palbocilif 125 mg
Please mention the quantity or the information you need. For side effects, use the pharmacovigilance form instead.